163 related articles for article (PubMed ID: 35464007)
21. Astragalus polysaccharides inhibit ovarian cancer cell growth via microRNA-27a/FBXW7 signaling pathway.
Guo Y; Zhang Z; Wang Z; Liu G; Liu Y; Wang H
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32159214
[TBL] [Abstract][Full Text] [Related]
22. Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines.
Zheng AW; Chen YQ; Fang J; Zhang YL; Jia DD
Biomed Pharmacother; 2017 May; 89():1172-1177. PubMed ID: 28320083
[TBL] [Abstract][Full Text] [Related]
23. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
Bahar E; Kim JY; Kim HS; Yoon H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
[TBL] [Abstract][Full Text] [Related]
24. Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway.
Gao L; Chen M; Ouyang Y; Li R; Zhang X; Gao X; Lin S; Wang X
Life Sci; 2018 Jun; 202():188-194. PubMed ID: 29625193
[TBL] [Abstract][Full Text] [Related]
25. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
26. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
27. MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy.
Chen J; Wang Q; Yin FQ; Zhang W; Yan LH; Li L
Am J Transl Res; 2015; 7(9):1510-27. PubMed ID: 26550452
[TBL] [Abstract][Full Text] [Related]
28. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer.
Song M; Cui M; Liu K
Eur J Med Chem; 2022 Mar; 232():114205. PubMed ID: 35217497
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
[TBL] [Abstract][Full Text] [Related]
32. Tobacco Mosaic Virus-Delivered Cisplatin Restores Efficacy in Platinum-Resistant Ovarian Cancer Cells.
Franke CE; Czapar AE; Patel RB; Steinmetz NF
Mol Pharm; 2018 Aug; 15(8):2922-2931. PubMed ID: 28926265
[TBL] [Abstract][Full Text] [Related]
33. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.
Musiani D; Hammond DE; Cirillo L; Erriquez J; Olivero M; Clague MJ; Di Renzo MF
J Proteome Res; 2014 Nov; 13(11):4970-82. PubMed ID: 25099161
[TBL] [Abstract][Full Text] [Related]
34. miR-548e Sponged by ZFAS1 Regulates Metastasis and Cisplatin Resistance of OC by Targeting CXCR4 and let-7a/BCL-XL/S Signaling Axis.
Zhang J; Quan LN; Meng Q; Wang HY; Wang J; Yu P; Fu JT; Li YJ; Chen J; Cheng H; Wu QP; Yu XR; Yun HY; Huang SG
Mol Ther Nucleic Acids; 2020 Jun; 20():621-638. PubMed ID: 32353736
[TBL] [Abstract][Full Text] [Related]
35. LINC-PINT suppresses tumour cell proliferation, migration and invasion through targeting miR-374a-5p in ovarian cancer.
Hao T; Huang S; Han F
Cell Biochem Funct; 2020 Dec; 38(8):1089-1099. PubMed ID: 32638404
[TBL] [Abstract][Full Text] [Related]
36. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
37. Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells.
Gao J; Wang Z; Fu J; A J; Ohno Y; Xu C
Exp Ther Med; 2021 Sep; 22(3):935. PubMed ID: 34335884
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
39.
Yang H; Zhang X; Zhu L; Yang Y; Yin X
DNA Cell Biol; 2021 Jun; 40(6):821-832. PubMed ID: 34030482
[TBL] [Abstract][Full Text] [Related]
40. Truncated Bid Regulates Cisplatin Response via Activation of Mitochondrial Apoptosis Pathway in Ovarian Cancer.
Dai Y; Zhao XJ; Li F; Yuan Y; Yan DM; Cao H; Huang XY; Hu Z; Ma D; Gao QL
Hum Gene Ther; 2020 Mar; 31(5-6):325-338. PubMed ID: 32024383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
